welcome
Reuters

Reuters

Health

Health

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

Reuters
Summary
Nutrition label

79% Informative

Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners .

The investment firms have also offered an additional $6.84 per share, contingent upon achieving certain sales milestones, which represents a payment of about $66.48 million .

Under the agreement, bluebird stockholders will receive $ 3 per share in cash.

VR Score

89

Informative language

95

Neutral language

60

Article tone

formal

Language

English

Language complexity

50

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.